Unknown statusInterventionalNot ApplicableUpdated May 8, 2023
Interaction Between Nalbuphine and Morphine in PCA | NCT00155233 | Trialant
Unknown statusInterventionalPhase 4Updated Nov 23, 2005
Interaction Between Nalbuphine and Morphine in PCA
Interaction Between Nalbuphine and Morphine in Postoperative PCA for Gynecologic Patients
ClinicalTrials.gov ID
NCT00155233
Lead Sponsor
National Taiwan University HospitalOTHER
Overall Status
Unknown status
Study Type
Interventional
Phase
Phase 4
Enrollment
200
Last Update Posted
Nov 23, 2005Estimated
Start Date
Jan 2005
Official Title
Interaction Between Nalbuphine and Morphine in Postoperative PCA for Gynecologic Patients
Brief Summary
Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist
This study was designed to investigate the interaction between nalbuphine and morphine
Detailed Description
Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist
This study was designed to investigate the interaction between nalbuphine and morphine
The analgesic effect and opioid-related side effects will be investigated
Postoperative Pain
Nalbuphine and morphine
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18-65 y/o
Female patients of ASA physical status I to III
Scheduled for elective abdominal hysterectomy, myomectomy, or excision of ovarian tumor
Exclusion Criteria:
Patients with a definite diagnosis of chronic pain syndrome, psychiatric disorders, or drug abuse (include opioids, NSAIDs, sedatives, antidepressants)
Intraoperative fentanyl use > 3 μg/kg
Patients with definite diagnosis of esophageal reflux syndrome
Use of sedatives, antiemetics, or antipruritics within 24 hours before operation